{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T18:35:47Z","timestamp":1787337347596,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The onset of symptom improvement following intravesical onabotulinum toxinA for urgency urinary incontinence is not well known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate the early efficacy of intradetrusor onabotulinumtoxinA for the treatment of urgency urinary incontinence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>We performed a prospective observational study of women undergoing intradetrusor onabotulinumtoxinA for the treatment of urgency urinary incontinence. Adult women receiving an initial or subsequent injection of 100 units of intradetrusor onabotulinumtoxinA were included. Participants completed 3-day baseline voiding diaries, the Urinary Distress Inventory-6, and Incontinence Impact Questionnaire-7 before the procedure. Voiding diaries, Urinary Distress Inventory-6, and Incontinence Impact Questionnaire-7 were repeated daily for 14 days postprocedure. Statistical analysis of paired data (preprocedure and postprocedure) was performed using the Wilcoxon signed-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one participants completed baseline and follow-up questionnaires. The median (range) baseline Urinary Distress Inventory-6 was 33 (8\u201371) and the Incontinence Impact Questionnaire-7 was 38 (0\u2013100). The median baseline daily voids, urgency urinary incontinence episodes, urgency episodes, and nocturia episodes were 13 (8\u201320), 5 (2\u201315), 8 (3\u201317), and 4 (0\u20136), respectively. For all measures, day 1 outcomes were significantly improved from baseline. Day 1 median Urinary Distress Inventory-6 was 25 (0\u201367), Incontinence Impact Questionnaire-7 was 24 (0\u201381), daily voids were 10 (5\u201320), daily urgency urinary incontinence episodes were 2 (0\u201315), daily urgency episodes were 3 (0\u201320), and daily nocturia episodes were 2 (0\u20134). Significant improvement persisted over the 14-day follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Women undergoing intradetrusor onabotulinumtoxinA for urgency urinary incontinence had significant subjective and objective improvement 1 day postprocedure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/spv.0000000000001807","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:00:29Z","timestamp":1769090429000},"page":"1103-1110","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Early Onset of Intradetrusor OnabotulinumtoxinA for Urgency Urinary Incontinence"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7826-3765","authenticated-orcid":false,"given":"Sarah","family":"Ashmore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret G.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Mucasey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Kenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"issue":"1","key":"R1-20260821","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"R2-20260821","first-page":"181","article-title":"Updated prevalence of urinary incontinence in women: 2015\u20132018 national population-based survey data","volume":"28","author":"Patel","year":"2022","journal-title":"Urogynecology"},{"issue":"8","key":"R3-20260821","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/nau.20709","article-title":"The impact of female urinary incontinence and urgency on quality of life and partner relationship","volume":"28","author":"Margareta","year":"2009","journal-title":"Neurourol Urodyn"},{"issue":"10","key":"R4-20260821","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/ijcp.12164","article-title":"Comorbidities and personal burden of urgency urinary incontinence: a systematic review","volume":"67","author":"Coyne","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"6S","key":"R5-20260821","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J Urol"},{"issue":"1","key":"R6-20260821","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cct.2011.09.019","article-title":"Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial","volume":"33","author":"Visco","year":"2012","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"R7-20260821","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cct.2014.01.009","article-title":"The refractory overactive bladder: sacral neuromodulation vs. botulinum toxin assessment: ROSETTA trial","volume":"37","author":"Amundsen","year":"2014","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"R8-20260821","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study","volume":"196","author":"Nitti","year":"2016","journal-title":"J Urol"},{"issue":"1","key":"R9-20260821","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.eururo.2018.02.011","article-title":"Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial","volume":"74","author":"Amundsen","year":"2018","journal-title":"Eur Urol"},{"key":"R10-20260821","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00404-012-2349-8","article-title":"Botox\u00ae for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection","volume":"286","author":"Granese","year":"2012","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"R11-20260821","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2011.12.011","article-title":"Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates","volume":"61","author":"Dowson","year":"2012","journal-title":"Eur Urol"},{"issue":"1","key":"R12-20260821","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.eururo.2007.12.029","article-title":"Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity","volume":"54","author":"Kalsi","year":"2008","journal-title":"Eur Urol"},{"issue":"7","key":"R13-20260821","first-page":"450","article-title":"Early and consistent improvements in urinary symptoms and quality of life with onabotulinumtoxinA in patients with overactive bladder and urinary incontinence: results from a randomized, placebo-controlled, phase IV clinical trial","volume":"27","author":"McCammon","year":"2021","journal-title":"Urogynecology"},{"issue":"3","key":"R14-20260821","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00192-022-05252-z","article-title":"Patient perceived improvement and medication resumption rates after intradetrusor onabotulinumtoxina for idiopathic urgency urinary incontinence","volume":"34","author":"Kocher","year":"2023","journal-title":"Int Urogynecol J"},{"issue":"2","key":"R15-20260821","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/nau.1930140206","article-title":"Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory","volume":"14","author":"Uebersax","year":"1995","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"R16-20260821","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ajog.2009.02.007","article-title":"The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire","volume":"200","author":"Barber","year":"2009","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"R18-20260821","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","article-title":"Botulinum toxin A (Botox\u00ae) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review","volume":"53","author":"Karsenty","year":"2008","journal-title":"Eur Urol"},{"issue":"7","key":"R19-20260821","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1007\/s00415-022-10995-2","article-title":"Time to onset and duration of botulinum toxin efficacy in movement disorders","volume":"269","author":"Ledda","year":"2022","journal-title":"J Neurol"},{"issue":"3","key":"R20-20260821","first-page":"105","article-title":"Botulinum toxin type a: evaluation of onset and satisfaction","volume":"38","author":"Alouf","year":"2018","journal-title":"Plast Aesthet Nurs"},{"issue":"1","key":"R21-20260821","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000083259","article-title":"Botulinum toxin: mechanisms of action","volume":"53","author":"Dressler","year":"2005","journal-title":"Eur Neurol"},{"issue":"1","key":"R22-20260821","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.22445","article-title":"Targets for botulinum toxin in the lower urinary tract","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"R23-20260821","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1124\/jpet.110.169342","article-title":"Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers","volume":"334","author":"Lawrence","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"R24-20260821","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.neuint.2004.06.001","article-title":"Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury","volume":"45","author":"Khera","year":"2004","journal-title":"Neurochem Int"},{"issue":"7","key":"R25-20260821","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/bju.12266","article-title":"Onabotulinumtoxin A significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium","volume":"112","author":"Collins","year":"2013","journal-title":"BJU Int"},{"issue":"2","key":"R26-20260821","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2005.04.019","article-title":"A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction","volume":"48","author":"Rapp","year":"2005","journal-title":"Eur Urol"}],"container-title":["Urogynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SPV.0000000000001807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T18:00:20Z","timestamp":1787335220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/SPV.0000000000001807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/spv.0000000000001807","relation":{},"ISSN":["2771-1897"],"issn-type":[{"value":"2771-1897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"2025-05-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}